1. Home
  2. DETX vs CTXR Comparison

DETX vs CTXR Comparison

Compare DETX & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Defense Holdings Ltd. Common Shares

DETX

Liberty Defense Holdings Ltd. Common Shares

N/A

Current Price

$3.62

Market Cap

20.5M

ML Signal

N/A

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

N/A

Current Price

$0.56

Market Cap

18.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DETX
CTXR
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.5M
18.7M
IPO Year
2022
2010

Fundamental Metrics

Financial Performance
Metric
DETX
CTXR
Price
$3.62
$0.56
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
15.8K
803.5K
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.38
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.78
$0.47
52 Week High
$4.25
$2.19

Technical Indicators

Market Signals
Indicator
DETX
CTXR
Relative Strength Index (RSI) 50.37 45.30
Support Level $2.78 $0.51
Resistance Level $4.24 $0.61
Average True Range (ATR) 0.34 0.08
MACD 0.08 0.00
Stochastic Oscillator 49.66 21.32

Price Performance

Historical Comparison
DETX
CTXR

About DETX Liberty Defense Holdings Ltd. Common Shares

Liberty Defense Holdings Ltd is engaged in the development and commercialization of security detection technologies such as airports, stadiums, schools, and more. The company's Hexwave product utilizes millimeter wave technology and Advanced 3D imaging to detect concealed threats. In addition to HEXWAVE, the company has licensed High-Definition Advanced Imaging Technology (HD-AIT) for body and shoe scanning. The Company operates through three distinct segments: Corporate, HEXWAVE, and Contract. The company generates the majority of its revenue from the Contract segment. Geographically, the company generates the majority of its revenue from the United States.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: